2 news items
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LBPH
10 Jun 24
:
The PACIFIC OLE Study is a 52-week Phase 2, open-label, long-term safety study of bexicaserin in participants
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
LBPH
2 May 24
long
- Prev
- 1
- Next